1245 related articles for article (PubMed ID: 27392913)
1. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
[TBL] [Abstract][Full Text] [Related]
2. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
Goto S; Gomi F; Ueno C; Nishida K
Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
[TBL] [Abstract][Full Text] [Related]
3. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
4. PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.
Hwang S; Kang SW; Kim SJ; Jang JW; Kim KT
Retina; 2019 Jun; 39(6):1117-1124. PubMed ID: 29517581
[TBL] [Abstract][Full Text] [Related]
5. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
6. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M
J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
[TBL] [Abstract][Full Text] [Related]
7. Isolated pigment epithelium detachment: evidence for relation to central serous chorioretinopathy and effect of photodynamic therapy.
Arif F; Pryds A; Larsen M
Acta Ophthalmol; 2018 Dec; 96(8):821-827. PubMed ID: 30246489
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
[TBL] [Abstract][Full Text] [Related]
9. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.
Russo A; Turano R; Morescalchi F; Gambicorti E; Cancarini A; Duse S; Costagliola C; Semeraro F
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732
[TBL] [Abstract][Full Text] [Related]
10. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.
Iacono P; Tedeschi M; Boccassini B; Chiaravalloti A; Varano M; Parravano M
Retina; 2019 May; 39(5):980-987. PubMed ID: 29346241
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy for steroid-associated central serous chorioretinopathy.
Lee TG; Kim JE
Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080
[TBL] [Abstract][Full Text] [Related]
12. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
13. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
14. CLINICAL FEATURES OF FLAT IRREGULAR PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH CHOROIDAL NEOVASCULARIZATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Guo J; Tang W; Liu W; Chang Q; Xu G
Retina; 2021 Jan; 41(1):199-207. PubMed ID: 32251241
[TBL] [Abstract][Full Text] [Related]
15. Spectral domain optical coherence tomography and angiographic findings in multifocal posterior pigment epitheliopathy treated with low-fluence photodynamic therapy.
Kuroyanagi K; Sakai T; Kasai K; Tsuneoka H
Clin Exp Optom; 2013 Jan; 96(1):126-9. PubMed ID: 22784102
[TBL] [Abstract][Full Text] [Related]
16. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
[TBL] [Abstract][Full Text] [Related]
17. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment.
Saito M; Iida T; Nagayama D
Br J Ophthalmol; 2008 Dec; 92(12):1642-7. PubMed ID: 18782798
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy for variant central serous chorioretinopathy: efficacy and side effects.
Gupta B; Mohamed MD
Ophthalmologica; 2011; 225(4):207-10. PubMed ID: 21325872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]